Enanta Pharmaceuticals PE ratio ENTA

Share price divided by earnings per share over the last twelve months, since 2014.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 42.1×; Aug 2020
10-year median: 25.8×
10-year range: 15.0× to 99.2×
Peer median: 11.5×

Enanta Pharmaceuticals has no meaningful PE ratio today: it lost $2.41 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Aug 2020, at 42.1×.

On the days it had one over the last ten years, its median was 25.8×, from 15.0× in Nov 2016 to 99.2× in Feb 2018.

PE ratio over time

median 25.8×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2020	42.1×	23.2×	49.4×
2019	28.2×	19.2×	30.0×
2018	20.2×	18.5×	99.2×
2017	66.7×	28.8×	66.7×
2016	29.9×	5.6×	30.8×
2015	8.1×	6.3×	28.7×
2014	29.4×	22.2×	29.4×

Against its peers

Companies in Drug Manufacturers - General nearest Enanta Pharmaceuticals' size, closest first, today.

Company	PE ratio
ENTAEnanta Pharmaceuticals	n/m
ARVNArvinas	45.6×
NATRNatures Sunshine Products	12.0×
PBYIPuma Biotechnology	21.2×
IRWDIronwood Pharmaceuticals	4.5×
ZVRAZevra Therapeutics	10.5×
CRMDCorMedix	3.7×
COLLCollegium Pharmaceutical	18.5×
ABUSArbutus Biopharma	5.4×
AMPHAmphastar Pharmaceuticals	14.8×
OMEROmeros	10.9×
Peer median	11.5×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Enanta Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.